Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Pick a track — progress rings update as you complete lessons.
6 lessons
9mGLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.
9mRetatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
8mTesamorelin has one of the stronger human-data profiles in the peptide space. A 2026 meta-analysis helps clarify what it improves, what it does not, and how to track the signal honestly.
7mA new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.
11mA 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.
Also available at /blog for legacy links.